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A B S T R A C T
Based on histological findings, calcifying fibrous tumor (CFT) may be a late (burned out) stage of inflammatory
myofibroblastic tumor (IMT). This concept, however, has not been proven by molecular means.
Five CFTs were analyzed for IMT-related rearrangements in ALK, ROS1 and RET using fluorescence in situ
hybridization (FISH). Additionally, genome-wide methylation patterns were investigated and compared with
IMT (n= 7), leiomyoma (n= 7), angioleiomyoma (n=9), myopericytoma (n= 7) and reactive soft tissue le-
sions (n=10) using unsupervised hierarchical cluster analysis and t distributed stochastic neighbor embedding.
CFT patients, 4 females and 1 male, had a median age of 20 years ranging from 7 to 43 years. Two patients
were younger than 18 years old. The tumors originated in the abdomen (n= 4) and axilla (n=1).
Histologically, all lesions were (multi) nodular and hypocellular consisting of bland looking (myo)fibroblasts
embedded in a collagenous matrix with calcifications.
FISH analysis brought up negative results for ALK, RET and ROS1 rearrangements. However, genome-wide
methylation analysis revealed overlapping methylation patterns of CFT and IMT forming a distinct homogeneous
methylation cluster with exception of one case clustering with myopericytoma/angioleiomyoma.
In conclusion, DNA methylation profiling supports the concept that CFT and IMT represent both ends of a
spectrum of one entity with CFT being the burn out stage of IMT.
1. Introduction
Calcifying fibrous tumor (CFT) is a rare benign mesenchymal lesion
occurring in both children and (young) adults [1-5]. The most common
location of CFT is the abdominal cavity including the gastrointestinal
tract, but its origin varies with occurrence in soft tissues and at other
visceral sites [1,2,5-8]. Histologically, CFT is characterized by a hypo-
cellular bland-looking (myo)fibroblastic proliferation associated with
dense collagen, chronic inflammation and variably prominent psam-
momatous or dystrophic calcifications [2,9,10]. Some hybrid lesions
with histological features of CFT and inflammatory myofibroblastic
tumors (IMT) have been reported suggesting a link between CFT and
IMT [11-13]. However, this concept is controversially discussed be-
cause strong evidence was missing so far. This study investigated the
relation between CFT and IMT by comparing the genome-wide me-
thylation patterns of both CFT and IMT alongside myopericytoma,
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angioleiomyoma, leiomyoma and reactive soft tissue lesions. Further-
more, we performed FISH for ALK, ROS1 and RET on CFTs as re-
arrangements of these genes are the genetic hallmark of IMT.
2. Material and methods
The study was conducted in accordance with the Code of Conduct of
the Federation of Medical Scientific Societies.
Patients with CFT were selected using the World Health
Organization (WHO) criteria [10]. A total of five cases were obtained
from our (referral) files. Clinical details were obtained from the records.
H&E slides were reviewed.
2.1. FISH ALK, ROS1 and RET
Fresh cut 4 μm sections of formalin-fixed paraffin embedded tissue
were submitted to dual-color fluorescence in situ hybridization (FISH)
analysis using three break-apart probes for ALK, ROS1 and RET. The
probe sets were developed at Cytocell (Cambridge, UK). FISH was
performed according the standard methods. At least 50 nuclei per
sample were counted.
2.2. DNA isolation, genome-wide DNA methylation data generation and
pre-processing
Representative tumor tissue with highest available tumor content
was chosen for DNA extraction. The Maxwell® 16 FFPE Plus LEV DNA
Kit or the Maxwell® 16 Tissue DNA Purification Kit (for frozen tissue)
was applied on the automated Maxwell device (Promega, Madison, WI,
USA) according to the manufacturer's instructions. All tumors had a
total amount of> 100 ng DNA and were suitable for the array-based
DNA methylation analysis. All tumors were subjected to Illumina
Infinium HumanMethylation450 (450k) BeadChip or the successor
EPIC/850k BeadChip (Illumina, San Diego, USA) analysis at the
Genomics and Proteomics Core Facility of the German Cancer Research
Center (DKFZ) Heidelberg. DNA methylation data were normalized by
performing background correction and dye bias correction (shifting of
negative control probe mean intensity to zero and scaling of normal-
ization control probe mean intensity to 20,000, respectively). Probes
targeting sex chromosomes, probes containing multiple single nucleo-
tide polymorphisms and those that could not be uniquely mapped were
removed. Probes from the EPIC array were excluded if the predecessor
Illumina Infinium 450k BeadChip did not cover them, thereby making
data generated by both 450k and EPIC feasible for subsequent analyses.
In total, 438,370 probes were kept for analysis.
2.3. Unsupervised clustering, t-SNE analysis and cumulative copy number
plotting
For unsupervised hierarchical clustering, we selected 10,000 probes
that showed the highest median absolute deviation (MAD) across the
beta values. Samples were hierarchically clustered using the Euclidean
distance and Ward's linkage method. Hierarchical clustering using
Euclidean distance and complete linkage reordered methylation probes.
The unscaled methylation levels were shown in a heat map from un-
methylated state (blue color) to methylated state (red color). For un-
supervised 2D representation of pairwise sample correlations, di-
mensionality reduction by t distributed stochastic neighbor embedding
(t-SNE) was performed using the 10,000 most variable probes, a per-
plexity of 20 and 2500 iterations. Novel methylation groups were tested
for stability by varying the number of the most variable probes.
The control group consisted of IMT (n=7), leiomyoma (n=7),
angioleiomyoma (n=9), myopericytoma (n=7) and reactive soft
tissue lesions (n=10).
3. Results
3.1. Clinical data
The clinical features of the CFT patients studied are summarized in
Table 1. The study consisted of 4 females and 1 male. The ages ranged
from 7 to 43 years, with a median of 20 years. Two patients were
younger than 18 years old. The tumors originated in the abdomen
(n=4) and axilla (n=1).
3.2. Histological data
All lesions were (multi)nodular with hypocellularity and a high
amount of hyalinized collagen. (Myo)fibroblastic cells, haphazardly
distributed, showed inconspicuous nuclei and scant cytoplasm.
Calcifications and lymphoplasmacytic inflammatory infiltrate, scattered
throughout the lesion, were present in all of the cases (Fig. 1). Hyali-
nized vessels were observed.
3.3. FISH data
All five cases were available for ALK, RET and ROS1 FISH, but re-
arrangements were not observed in any case.
3.4. Genome-wide methylation analysis
Four of the five CFTs formed a homogeneous methylation group
with the IMTs by clustering and t-SNE analysis (Fig. 2), which remained
stable when varying the number of CpGs (Cytosine-phosphatidyl-Gua-
nine) used. The single CFT outlier assigned to the distinct methylation
cluster of myopericytoma/angioleioma. Leiomyoma and reactive le-
sions clustered separately.
Table 1
Clinical data and histopathological diagnoses.
Patient
number
Sex Age at
diagnosis
Location of
tumor
Tumor type
1 F 7 Axilla Calcifying fibrous tumor
2 F 20 Abdomen Calcifying fibrous tumor
3 F 43 Upper
abdomen
Myopericytoma/
angioleioma
4 F 38 Abdomen Calcifying fibrous tumor
5 M 13 Omentum Calcifying fibrous tumor
Fig. 1. Histologically, cases were hypocellular and possessed a prominent col-
lagenous matrix with psammomatous calcifications and an inflammatory re-
action.
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4. Discussion
Calcifying fibrous tumors (CFT) were first described in 1988 by
Rosenthal and Abdul-Karim under the name “childhood fibrous tumor
with psammoma bodies”. In 1993 Fetsch et al. reported on several cases
of the files of the Armed Forces Institute of Pathology expanding the age
range and using the term calcifying fibrous pseudotumor [2,9]. Later
on, these lesions were considered neoplastic and designated as calci-
fying fibrous tumor [6].
Since its original description the pathogenesis is still under debate.
Based on clinicopathological characteristics a relationship with in-
flammatory myofibroblastic tumor (IMT) has been suggested and sub-
sequently controversially discussed [6,10,12-14]. Coffin et al. de-
termined three phenotypes of IMT: 1) myxoid, vascular, inflammatory,
2) compact spindle cells with intermingled inflammatory cells, 3) dense
plate-like collagen, reflecting high variability of IMT morphology with
the latter being probably a late stage resembling CFT [15]. To the best
of our knowledge, three cases have been reported with coexisting his-
tological patterns of CFT and IMT arguing that CFT is a late stage of IMT
[11-13]. However, ALK, a consistent marker of IMT, has been found
only exceptionally in CFT [16]. ALK rearrangement, or alternatively
rearrangement of ROS1 and RET shown in 56–61.1%, 5.6–10% and
1.6% of investigated cases, respectively, are the driver genetic events in
IMTs and FISH analysis can aid as diagnostic tool to confirm the di-
agnosis [17,18]. Rearrangements of these genes were not detected in
any of our CFT cases. When CFT is the advanced stage of regressed IMT,
it is not surprising that the mentioned genetic changes and the corre-
sponding proteins are absent seemingly due to substitution of scar-like
tissue and a decreased amount of lesional cells.
The most convincing argument that CFT and IMT form a spectrum
with CFT being the burned out end we found by methylation profiling
showing overlapping methylation patterns. It appears that this assay is
of a higher sensitivity in comparison to rearrangement analysis using
FISH, at least when we deal with a lesion with features of marked re-
gression. Another explanation could be that the subset of IMT going
into regression shows alternative fusion genes, e.g. NTRK3, PDGFRB
and IGF1R [17,19,20].
CFTs are benign with exceptional recurrences whereas IMTs may
behave aggressively, even rarely [10]. One could argue that a subset of
benign behaving IMTs go into regression offering a CFT appearance.
This is also confirmed by cases with morphological aspects of both, IMT
and CFT [11-13].
One of our cases (case 3) clustered with myopericytoma/angio-
leiomyoma. From the morphological point of view this case was not
different showing that a late stage myopericytoma/angioleiomyoma
may have the same burn-out features as CFT.
In conclusion, we could show by methylation profiling that CFT has
the same epigenetic profile as IMT and support a relationship with CFT
being probably a late, burned out stage of IMT irrespective of negative
fusion gene analysis leading to lack of expression of the corresponding
proteins in CFT.
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